Biogen Inc. (BIIB) Yield on Cost (YOC): N/A
The yield on cost (YOC) for Biogen Inc. (BIIB) is N/A.
BIIB Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
N/A
Interactive Yield on Cost Calculator
Project custom investment returns for Biogen Inc. (BIIB) based on your custom cost basis.
Starting Yield
1.00%
Ending YOC
3.19%
Year 15 Dividend
$6.34
Cum. Dividends Recd.
$58.65
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $2.00 | — | 1.00% | $0.00 |
| Year 1 | $2.16 | +8.00% | 1.08% | $2.16 |
| Year 2 | $2.33 | +8.00% | 1.17% | $4.49 |
| Year 3 | $2.52 | +8.00% | 1.27% | $7.01 |
| Year 4 | $2.72 | +8.00% | 1.37% | $9.73 |
| Year 5 | $2.94 | +8.00% | 1.48% | $12.67 |
| Year 6 | $3.17 | +8.00% | 1.59% | $15.85 |
| Year 7 | $3.43 | +8.00% | 1.72% | $19.27 |
| Year 8 | $3.70 | +8.00% | 1.86% | $22.98 |
| Year 9 | $4.00 | +8.00% | 2.01% | $26.97 |
| Year 10 | $4.32 | +8.00% | 2.17% | $31.29 |
| Year 11 | $4.66 | +8.00% | 2.34% | $35.95 |
| Year 12 | $5.04 | +8.00% | 2.53% | $40.99 |
| Year 13 | $5.44 | +8.00% | 2.73% | $46.43 |
| Year 14 | $5.87 | +8.00% | 2.95% | $52.30 |
| Year 15 | $6.34 | +8.00% | 3.19% | $58.65 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
Biogen Inc. Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Biogen Inc.
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher A. Viehbacher